- BriaCell Therapeutics Corp. will reveal important information about Bria-IMT and Bria-OTS at two leading conferences – the ASCO-SITC Clinical Immuno-Oncology Symposium and the American Association of Cancer Research’s annual meeting
- New information will also be made available about the company’s HLA-identification test, BriaDX, which is aimed at identifying patients most likely to benefit from Bria-IMT
- In addition, BriaCell founder and director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit in France
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company with a focus on immune-oncology, is expected to announce findings pertaining to the effectiveness and mode of action of its lead product candidate – Bria-IMT – at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, according to a company press release (http://ibn.fm/eH3P5). The key oncology conference will be taking place from February 28 to March 2, 2019, in San Francisco.
The company was selected to present a poster highlighting the latest findings related to the mechanism of action of Bria-IMT – an immunotherapy solution for patients with advanced breast cancer. BriaCell Therapeutics Corp. will also present information regarding BriaDX, the companion diagnostic test that aims to identify the patient groups anticipated to benefit the most from the treatment. In addition, BriaCell will provide the latest information about its personalized, off-the-shelf immunotherapy solution called Bria-OTS.
Following the presentation at the symposium, BriaCell will post a copy of the poster on BriaCell.com/Investor-Relations/Presentations.
The company has also announced that BriaCell founder and director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit to take place in Paris on March 21-22, 2019. This year’s summit theme is going to be “Rediscovering Novel Approaches towards Cure for Breast Cancer and Women’s Health.”
Finally, BriaCell Therapeutics will present a poster at the highly prestigious American Association of Cancer Research’s (“AACR”) annual meeting that will take place from March 29 to April 3, 2019, in Atlanta, Georgia.
BriaCell has completed a 23-subject phase I/IIa trial of Bria-IMT in patients with advanced breast cancer. Significant tumor regression was observed in patients who matched Bria-IMT at human leukocyte antigen (“HLA”) types. During the ASCO-SITC Clinical Immuno-Oncology Symposium, BriaCell is set to detail these findings and provide an analysis of immunologic factors (HLA matching is currently being evaluated as a factor for predicting the tumor response in breast cancer patients treated with a combination of Bria-IMT and KEYTRUDA).
During the Atlanta conference, BriaCell Therapeutics Corp. is expected to provide additional information about the Bria-IMT mechanism of action. This type of data is derived from molecular and clinical findings, both supporting the development of Bria-OTS.
Bria-OTS is similar to Bria-IMT, because it also consists of a set of cell lines. The main difference is that Bria-OTS will be engineered to produce different HLA types to match individual patients. Bria-OTS is anticipated to produce an increased response rate due to HLA matching in comparison to unmatched therapeutic approaches.
The personalized off-the-shelf immunotherapy solution is still in the development phase. There are plans for Bria-OTS to enter the clinic later in 2019.
BriaCell Therapeutics Corp. is an immuno-oncology-focused biotech company that develops both targeted and safe cancer management approaches. The company’s lead candidate, Bria-IMT, has so far demonstrated substantial ability to provoke tumor shrinkage with excellent tolerability. Bria-OTS is anticipated to come at a lower production cost and have fewer side effects than comparable personalized immunotherapies.
For more information, visit the company’s website at www.BriaCell.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.